Viridian Therapeutics, Inc. (VRDN)
VRDN Stock Price Chart
Explore Viridian Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze VRDN price movements and trends.
VRDN Company Profile
Discover essential business fundamentals and corporate details for Viridian Therapeutics, Inc. (VRDN) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jun 2014
Employees
143.00
CEO
Stephen F. Mahoney MBA
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
VRDN Financial Timeline
Browse a chronological timeline of Viridian Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 25 Feb 2026
Upcoming earnings on 11 Nov 2025
EPS estimate is -$0.79.
Earnings released on 6 Aug 2025
EPS came in at -$1.00 falling short of the estimated -$0.98 by -2.23%, while revenue for the quarter reached $75.00K , beating expectations by +59.57%.
Earnings released on 6 May 2025
EPS came in at -$0.87 surpassing the estimated -$0.95 by +8.42%, while revenue for the quarter reached $72.00K , beating expectations by +63.34%.
Earnings released on 27 Feb 2025
EPS came in at -$0.81 surpassing the estimated -$1.05 by +22.86%, while revenue for the quarter reached $72.00K , beating expectations by +44.00%.
Earnings released on 12 Nov 2024
EPS came in at -$1.15 falling short of the estimated -$1.11 by -3.60%, while revenue for the quarter reached $86.00K , beating expectations by +72.00%.
Earnings released on 8 Aug 2024
EPS came in at -$1.02 falling short of the estimated -$0.87 by -17.24%, while revenue for the quarter reached $72.00K , missing expectations by -10.00%.
Earnings released on 8 May 2024
EPS came in at -$0.79 surpassing the estimated -$1.07 by +26.17%, while revenue for the quarter reached $72.00K , beating expectations by +2.86%.
Earnings released on 27 Feb 2024
EPS came in at -$1.35 falling short of the estimated -$1.08 by -25.00%, while revenue for the quarter reached $72.00K , missing expectations by -53.30%.
Earnings released on 13 Nov 2023
EPS came in at -$1.09 surpassing the estimated -$1.22 by +10.66%, while revenue for the quarter reached $72.00K , missing expectations by -55.00%.
Earnings released on 8 Aug 2023
EPS came in at -$1.27 falling short of the estimated -$1.26 by -0.79%, while revenue for the quarter reached $72.00K , missing expectations by -28.00%.
Earnings released on 9 May 2023
EPS came in at -$1.61 falling short of the estimated -$1.00 by -61.00%, while revenue for the quarter reached $98.00K , missing expectations by -2.00%.
Earnings released on 8 Mar 2023
EPS came in at -$1.13 falling short of the estimated -$0.72 by -56.94%, while revenue for the quarter reached $105.00K , missing expectations by -79.41%.
Earnings released on 14 Nov 2022
EPS came in at -$0.86 surpassing the estimated -$0.87 by +1.15%, while revenue for the quarter reached $1.20M , beating expectations by +293.96%.
Earnings released on 15 Aug 2022
EPS came in at -$1.06 falling short of the estimated -$0.86 by -23.26%, while revenue for the quarter reached $256.00K , missing expectations by -5.30%.
Earnings released on 12 May 2022
EPS came in at -$0.98 falling short of the estimated -$0.92 by -6.52%, while revenue for the quarter reached $216.00K , missing expectations by -14.79%.
Earnings released on 10 Mar 2022
EPS came in at -$1.32 falling short of the estimated -$0.85 by -55.29%, while revenue for the quarter reached $214.00K , missing expectations by -37.57%.
Earnings released on 4 Nov 2021
EPS came in at -$1.25 falling short of the estimated -$1.19 by -5.04%, while revenue for the quarter reached $208.00K , missing expectations by -63.51%.
Earnings released on 11 Aug 2021
EPS came in at -$2.21 falling short of the estimated -$1.22 by -81.15%, while revenue for the quarter reached $1.09M , beating expectations by +42.88%.
Earnings released on 6 May 2021
EPS came in at -$2.91 falling short of the estimated -$0.61 by -377.05%, while revenue for the quarter reached $1.45M , missing expectations by -39.25%.
Earnings released on 25 Mar 2021
EPS came in at -$5.31 falling short of the estimated -$1.27 by -318.11%, while revenue for the quarter reached $54.00K .
Stock split effective on 13 Nov 2020
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 10 Nov 2020
EPS came in at -$1.50 surpassing the estimated -$1.99 by +24.62%.
VRDN Stock Performance
Access detailed VRDN performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.